EUVIMEDEUVIMED entdecken
Open Access

Impact of post‐chemotherapy classification on outcomes in stage III and IV unilateral favorable histology Wilms tumor: Pooled data from Children’s Oncology Group AREN0532, AREN0533, and AREN03B2 studies

Einfluss der postchemotherapeutischen Klassifikation auf die Outcomes bei unilateralem Wilms-Tumor mit günstiger Histologie im Stadium III und IV: gepoolte Daten aus den Children’s Oncology Group-Studien AREN0532, AREN0533 und AREN03B2

Nicholas F Evageliou iD, Lindsay A Renfro, Kelly L Vallance, Carly R Varela, Daniel J Benedetti iD, Nicholas G Cost, Peter F Ehrlich iD, John A Kalapurakal, Geetika Khanna, Jennifer H Aldrink iD, Richard D Glick, Michael V Ortiz und 9 weitere

Cancer · 01.10.2026 · 132 (19)

DOI: 10.1002/cncr.70610 ↗

Auf einen Blick

Bei 352 Kindern mit unilateralem FHWT war die postchemotherapeutische Histologie (PCH) mit dem ereignisfreien Überleben und dem Gesamtüberleben assoziiert. Die HR-Gruppe hatte die schlechtesten 4-Jahres-Ergebnisse.

Fragestellung

Ist die postchemotherapeutische Histologie (PCH) im COG-Behandlungskontext bei unilateralem FHWT mit den Outcomes assoziiert?

Methode

Analyse von 352 Patient:innen mit Stadium III oder IV FHWT aus AREN0532, AREN0533 oder AREN03B2 (2006–2019) mit verzögerter Nephrektomie, DD4A oder Regimen M und bekannter PCH.

Ergebnisse

PCH war prognostisch für EFS und OS (je p < .0001). 4-Jahres-EFS: LR 93 % (95 %-KI 86 %–100 %), IR 85 % (95 %-KI 81 %–89 %), HR 53 % (95 %-KI 35 %–81 %). 4-Jahres-OS: 96 % (95 %-KI 90 %–100 %), 93 % (95 %-KI 89 %–96 %), 62 % (95 %-KI 44 %–89 %).

Schlussfolgerung der Autor:innen

PCH ist bei unilateralem FHWT unter COG-Schemata ein signifikanter prognostischer Faktor und spricht stark dafür, sie in prospektiven COG-Studien zur therapeutischen Stratifizierung zu berücksichtigen.

Kernaussagen

  • PCH war mit EFS und OS signifikant assoziiert.
  • HR hatte deutlich schlechtere 4-Jahres-Outcomes als LR und IR.
  • 4-Jahres-OS: 96 % LR, 93 % IR, 62 % HR.

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, online erschienen am 17.09.2026. Verfasst von Nicholas F Evageliou und 20 weiteren Autor:innen. Beteiligte Einrichtung: Division of Oncology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Wilms Tumor, Kidney Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, St. Baldrick's Foundation, Solder True Life Foundation.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Improvements in therapy for patients with favorable histology Wilms tumor (FHWT) have relied on refinement of risk stratification for therapeutic assignment through identification of favorable and unfavorable prognostic factors. Although well established in International Society of Pediatric Oncology‐Renal Tumor Study Group protocols, the Children’s Oncology Group (COG) has not historically used post‐chemotherapy histology (PCH) to guide therapy. This study examines whether outcomes are associated with PCH classification in the COG treatment context.

Methods

The authors identified 2386 patients with stage III or IV FHWT enrolled on AREN0532, AREN0533, or AREN03B2‐only from 2006 to 2019. Inclusion criteria included delayed nephrectomy more than 5 and fewer than 16 weeks after initial biopsy, treatment on or as per protocol with DD4A or Regimen M, and known PCH classification and outcome.

Results

Of 352 included patients, 45 (12.7%) were classified as low risk (LR), 287 (81.5%) as intermediate risk (IR), and 20 (5.6%) as high risk (HR). PCH classification was significantly prognostic for event‐free survival (EFS) ( p < .0001) and overall survival (OS) ( p < .0001). Four‐year EFS for LR, IR, and HR groups was 93% (95% CI, 86%–100%), 85% (95% CI, 81%–89%), and 53% (95% CI, 35%–81%); 4‐year OS was 96% (95% CI, 90%–100%), 93% (95% CI, 89%–96%), and 62% (95% CI, 44%–89%). Compared with LR or IR, EFS and OS were significantly lower for HR, regardless of stage or treatment.

Conclusion

PCH is a significant prognostic factor in unilateral FHWT treated on COG regimens, strongly supporting its incorporation into therapeutic stratification in prospective COG trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Wilms TumorKidney NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleNeoplasm StagingChild, PreschoolPrognosisNephrectomyMaleInfantChildTreatment Outcome

Stichwörter der Autor:innen

Wilms tumorblastemal predominantdelayed nephrectomypost‐chemotherapy histologypreoperative chemotherapyrisk stratificationtherapeutic stratification

Autor:innen und Institutionen

  • Division of Oncology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
  • Division of Biostatistics, University of Southern California, and Children's Oncology Group, Los Angeles, California, USA.
  • Hematology and Oncology, Cook Children's Medical Center, Fort Worth, Texas, USA.
  • Johnson & Johnson, Spring House, Philadelphia, Pennsylvania, USA.
  • Division of Hematology/Oncology, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Department of Surgery, Division of Urology and the Surgical Oncology Program at Children's Hospital Colorado, University of Colorado School of Medicine, Aurora, Colorado, USA.

ORCID-Profile: Nicholas F Evageliou, Daniel J Benedetti, Peter F Ehrlich, Jennifer H Aldrink, Lauren N Parsons, Arnold C Paulino

Förderung

  • NCI NIH HHS
  • St. Baldrick's Foundation
  • Solder True Life Foundation
  • Clinician Scientist Research Specialist Award
  • Children's Oncology Group Biospecimen Bank Grant

Zitieren

APA

Evageliou, N. F., Renfro, L. A., Vallance, K. L., Varela, C. R., Benedetti, D. J., Cost, N. G., Ehrlich, P. F., Kalapurakal, J. A., Khanna, G., Aldrink, J. H., Glick, R. D., Ortiz, M. V., Parsons, L. N., Paulino, A. C., Artunduaga, M., Smith, E. A., Dix, D. B., Fernandez, C. V., Dome, J. S., …, & Mullen, E. A. (2026). Impact of post‐chemotherapy classification on outcomes in stage III and IV unilateral favorable histology Wilms tumor: Pooled data from Children’s Oncology Group AREN0532, AREN0533, and AREN03B2 studies. Cancer, 132(19). https://doi.org/10.1002/cncr.70610

Vancouver

Evageliou NF, Renfro LA, Vallance KL, Varela CR, Benedetti DJ, Cost NG, et al. Impact of post‐chemotherapy classification on outcomes in stage III and IV unilateral favorable histology Wilms tumor: Pooled data from Children’s Oncology Group AREN0532, AREN0533, and AREN03B2 studies. Cancer. 2026;132(19). doi:10.1002/cncr.70610

BibTeX
@article{Evageliou2026,
  author = {Evageliou, Nicholas F and Renfro, Lindsay A and Vallance, Kelly L and Varela, Carly R and Benedetti, Daniel J and Cost, Nicholas G and Ehrlich, Peter F and Kalapurakal, John A and Khanna, Geetika and Aldrink, Jennifer H and Glick, Richard D and Ortiz, Michael V and Parsons, Lauren N and Paulino, Arnold C and Artunduaga, Maddy and Smith, Ethan A and Dix, David B and Fernandez, Conrad V and Dome, Jeffrey S and Geller, James I and Mullen, Elizabeth A},
  title = {Impact of post‐chemotherapy classification on outcomes in stage III and IV unilateral favorable histology Wilms tumor: Pooled data from Children’s Oncology Group AREN0532, AREN0533, and AREN03B2 studies},
  journal = {Cancer},
  year = {2026},
  volume = {132},
  number = {19},
  doi = {10.1002/cncr.70610}
}
Kostenlos starten →